Champions Oncology Reports Record 2026 Revenue and Positive Adjusted EBITDA
Jul 27, 2026, 4:06 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The company posted a record top line, positive Adjusted EBITDA across all quarters, improved quarterly margins, and a debt-free balance sheet with cash of $4.9M. These factors support potential multiple expansion and upside in CSBR shares, assuming growth initiatives lead to higher recurring revenue and sustained profitability. Risks include reliance on non-GAAP metrics and the absence of explicit forward guidance.
AI summary
What happened, with direct paths to the underlying reporting
Champions Oncology posted FY2026 revenue of $59.4M, a 4% rise, and positive Adjusted EBITDA across all four quarters. Q4 revenue reached $13.8M with a 51% oncology services margin. The company continues investments in radiopharmaceuticals, its data platform, and commercial organization, while ending the year with $4.9M cash and no debt. The lack of recurring data license revenue in 2026 creates a base effect that investors will watch as growth initiatives mature.
FY2026 revenue reached a record $59.4M. YoY growth was 4%.
Q4 2026 revenue was $13.8M. Oncology services margin 51%.
FY2026 Adjusted EBITDA was $1.6M; quarterly EBITDA positive every quarter.
Investments continue in radiopharmaceuticals, data platform, and commercial org.
No debt; cash balance $4.9M at April 30, 2026; guidance not provided.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
